Literature DB >> 35349353

Hypoglycemia in Prospective Multicenter Study of Pregnancies with Pre-Existing Type 1 Diabetes on Sensor-Augmented Pump Therapy: The LOIS-P Study.

Ravinder Jeet Kaur1, Byron H Smith2, Basak Ozaslan3, Jordan E Pinsker4, Mari Charisse Trinidad1, Grenye O'Malley5, Donna Desjardins1, Kristin N Castorino4, Camilla Levister5, Corey Reid1, Shelly McCrady-Spitzer1, Selassie J Ogyaadu5, Mei Mei Church4, Molly Piper4, Walter K Kremers2, Barak Rosenn5, Francis J Doyle3, Eyal Dassau3, Carol J Levy5, Yogish C Kudva1.   

Abstract

Background: Pregnancies in type 1 diabetes are high risk, and data in the United States are limited regarding continuous glucose monitoring (CGM)-based hypoglycemia throughout pregnancy while on sensor-augmented insulin pump therapy. Materials and
Methods: Pregnant women with type 1 diabetes in the LOIS-P Study (Longitudinal Observation of Insulin use and glucose Sensor metrics in Pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps) were enrolled before 17 weeks gestation at three U.S. centers and we used their personal insulin pump and a study Dexcom G6 CGM. We analyzed data of 25 pregnant women for CGM hypoglycemia based on international consensus guidelines for percentage time <63 and 54 mg/dL, hypoglycemic events and prolonged hypoglycemia events for 24-h, daytime, and overnight periods, and severe hypoglycemia (SH) episodes.
Results: For a 24-h period, biweekly median percentage of time <63 mg/dL ranged from 0.8% at biweek 4-5 to 3.7% at biweek 14-15 with high variability throughout pregnancy. Median percentage of time <63 and 54 mg/dL was higher overnight than daytime (P < 0.01). Hypoglycemic events occurred throughout the pregnancy, ranged 1-4 events per 2 weeks, significantly decreased after the 20th week, and occurred predominantly during daytime (P < 0.01). For overnight period, hypoglycemia and events were more concentrated from 12 to 3 am. Seven prolonged hypoglycemia events without any associated SH occurred in four participants (16%), primarily overnight. Three participants experienced a single episode of SH. Conclusions: Our results suggest a higher overall risk of hypoglycemia throughout pregnancy during the overnight period with continued daytime risk of hypoglycemic events in pregnancies complicated by type 1 diabetes.

Entities:  

Keywords:  Continuous glucose monitoring; Hypoglycemia; Pregnancy; Prolonged hypoglycemia; Type 1 diabetes

Mesh:

Substances:

Year:  2022        PMID: 35349353      PMCID: PMC9353990          DOI: 10.1089/dia.2021.0479

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   7.337


  23 in total

1.  Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care.

Authors:  John L Kitzmiller; Jennifer M Block; Florence M Brown; Patrick M Catalano; Deborah L Conway; Donald R Coustan; Erica P Gunderson; William H Herman; Lisa D Hoffman; Maribeth Inturrisi; Lois B Jovanovic; Siri I Kjos; Robert H Knopp; Martin N Montoro; Edward S Ogata; Pathmaja Paramsothy; Diane M Reader; Barak M Rosenn; Alyce M Thomas; M Sue Kirkman
Journal:  Diabetes Care       Date:  2008-05       Impact factor: 19.112

2.  Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.

Authors:  Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman
Journal:  JAMA       Date:  2016-10-04       Impact factor: 56.272

3.  Insulin pump dosing across gestation in women with well-controlled type 1 diabetes mellitus.

Authors:  Hilary A Roeder; Thomas R Moore; Gladys A Ramos
Journal:  Am J Obstet Gynecol       Date:  2012-10       Impact factor: 8.661

4.  Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.

Authors:  Zoe A Stewart; Malgorzata E Wilinska; Sara Hartnell; Leanne K O'Neil; Gerry Rayman; Eleanor M Scott; Katharine Barnard; Conor Farrington; Roman Hovorka; Helen R Murphy
Journal:  Diabetes Care       Date:  2018-03-13       Impact factor: 19.112

5.  Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study.

Authors:  Dorte M Jensen; Peter Damm; Lars Moelsted-Pedersen; Per Ovesen; Jes G Westergaard; Margrethe Moeller; Henning Beck-Nielsen
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

6.  Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man.

Authors:  J D Veldhuis; A Iranmanesh; M L Johnson; G Lizarralde
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

7.  Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy.

Authors:  Helen R Murphy; Gerry Rayman; Katherine Duffield; Karen S Lewis; Susan Kelly; Balroop Johal; Duncan Fowler; Rosemary C Temple
Journal:  Diabetes Care       Date:  2007-07-31       Impact factor: 19.112

8.  Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange.

Authors:  Sarit Polsky; Mengdi Wu; Bruce W Bode; Stephanie N DuBose; Robin S Goland; David M Maahs; Nicole C Foster; Anne L Peters; Carol J Levy; Viral N Shah; Roy W Beck
Journal:  Diabetes Technol Ther       Date:  2018-07-10       Impact factor: 6.118

9.  Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study.

Authors:  Helen R Murphy; Ruth Bell; Cher Cartwright; Paula Curnow; Michael Maresh; Margery Morgan; Catherine Sylvester; Bob Young; Nick Lewis-Barned
Journal:  Diabetologia       Date:  2017-06-08       Impact factor: 10.122

10.  Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies.

Authors:  Karl Kristensen; Linda E Ögge; Verena Sengpiel; Karin Kjölhede; Annika Dotevall; Anders Elfvin; Filip K Knop; Nana Wiberg; Anastasia Katsarou; Nael Shaat; Lars Kristensen; Kerstin Berntorp
Journal:  Diabetologia       Date:  2019-03-23       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.